Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapiesLars Masanneck, Marc Pawlitzki, Leoni Rolfes et al.|Multiple Sclerosis and Related Disorders|2022Cited by 21
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or OfatumumabSven G. Meuth, Steffen Pfeuffer, Saskia Räuber et al.|Annals of Neurology|2024Cited by 19
Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohortPaula Quint, Tobias Ruck, Christina B. Schroeter et al.|Journal of Neurology|2024Cited by 18
Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With OcrelizumabSteffen Pfeuffer, Sven G. Meuth, Leoni Rolfes et al.|Neurology Neuroimmunology & Neuroinflammation|2023Cited by 10
Eculizumab treatment alters the proteometabolome beyond the inhibition of complementChristopher Nelke, Tobias Ruck, Christina B. Schroeter et al.|JCI Insight|2023Cited by 10